Salud financiera de hoja de balance de Axsome Therapeutics
Salud financiera controles de criterios 4/6
Axsome Therapeutics tiene un patrimonio de los accionistas total de $144.0M y una deuda total de $178.7M, lo que sitúa su ratio deuda-patrimonio en 124.1%. Sus activos y pasivos totales son $545.7M y $401.7M respectivamente.
Información clave
124.1%
Ratio deuda-patrimonio
US$178.69m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$331.44m |
| Patrimonio | US$144.04m |
| Total pasivo | US$401.69m |
| Activos totales | US$545.73m |
Actualizaciones recientes sobre salud financiera
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Recent updates
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years
Mar 19Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($460.5M) de AXSM superan a sus pasivos a corto plazo ($144.0M).
Pasivo a largo plazo: Los activos a corto plazo de AXSM ($460.5M) superan a sus pasivos a largo plazo ($257.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: AXSM tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de AXSM ha crecido de 111.4% a 124.1% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: AXSM tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si AXSM tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.